ABSTRACT
Longitudinal data analysis can improve our understanding of the influences on health trajectories across the life-course. There are a variety of statistical models which can be used, and their fitting and interpretation can be complex, particularly where there is a nonlinear trajectory. This paper provides a guide to describing nonlinear growth trajectories for repeatedly measured continuous outcomes using linear mixed-effects (LME) models with linear splines and natural cubic splines, nonlinear mixed effects Super Imposition by Translation and Rotation (SITAR) models, and latent trajectory models. The underlying model for each of the four approaches, the similarities and differences between models, and their advantages and disadvantages are described. Their applications and correct interpretation are illustrated by analysing repeated bone mass measures across three cohort studies with 8,500 individuals and 37,000 measurements covering ages 5-40 years. Linear and natural cubic spline LME models and SITAR provided similar descriptions of the mean bone growth trajectory and growth velocity, and the sex differences in growth patterns. Latent trajectory models identified up to four subgroups of individuals with distinct trajectories during adolescence and similar trajectories in childhood and adulthood. Recommendations for choosing a modelling approach are provided along with a discussion and signposting on further modelling extensions for analysing trajectory exposures and outcomes, and multiple cohorts. In summary, we present a resource for characterising nonlinear longitudinal growth trajectories, that could be adapted for other complex traits. Scripts and synthetic datasets are provided so readers can replicate trajectory modelling and visualisation using the open-source R software.
Competing Interest Statement
DAL reported grants from national and international government and charity funders, Roche Diagnostics, and Medtronic Ltd for work unrelated to this publication. KMT reported grants from national and international government and charity funders, for work unrelated to this publication. No other disclosures were reported.
Clinical Trial
This is a methods paper, not a trial
Funding Statement
This project has received funding from the European Union Horizon 2020 research and innovation programme under grant agreements No.733206 (LifeCycle) and No.874739 (LongITools).AE, KMT, RAH and DAL work in a unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_00011/3 & MC_UU_00011/3). RAH is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 215408/Z/19/Z). ASFK is supported by an Economic Social Research Council Postdoctoral Fellowship (Grant ref: ES/V011650/1). The UK Medical Research Council and Wellcome (Grant Ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grant funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). PBMAS was supported in part by funding from the Canadian Institutes of Health Research, the Saskatchewan Health Research Foundation (SHRF), The Dairy Farmers of Canada and the University of Saskatchewan. The funders had no role in the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This research reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ALSPAC study obtained ethics approval from the ALSPAC law and ethics committee and the local National Health Service research ethics committee. The BMDCS study was approved by the Institutional Review Board of each clinical center: Children Hospital of Los Angeles (Los Angeles, CA), Cincinnati Children Hospital Medical Center (Cincinnati, OH), Creighton University (Omaha, NE), Children Hospital of Philadelphia (CHOP) (Philadelphia, PA), and Columbia University (New York, NY). The PBMAS study was approved by the University of Saskatchewan's biomedical review committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Details of all available data and the processes and procedures involved in accessing the ALSPAC resource can be found in the ALSPAC study website, which includes a fully searchable data dictionary and variable search tool (http://www.bristol.ac.uk/alspac/researchers/our-data/). The BMDCS data can be accessed through the NICHD DASH website (https://dash.nichd.nih.gov/). Researchers interested in accessing the PBMAS data should contact Professor Adam DG Baxter-Jones (baxter.jones{at}usask.ca).
